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Abstract 
 
Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis 
(RA), but many patients do not respond adequately. In order to identify genetic predictors 
of response, we have combined data from two consortia to carry out a genome-wide study 
of response to MTX in 1424 early RA patients of European ancestry. Clinical endpoints were 
change from baseline to 6 months after starting treatment in swollen 28-joint count, tender 
28-joint count, C-reactive protein and the overall 3-component disease activity score 
(DAS28). No SNP reached genome-wide statistical significance for any outcome measure. 
The strongest evidence for association was with rs168201 in NRG3 (p=10-7 for change in 
DAS28). Some support was also seen for association with ZMIZ1, previously highlighted in a 
study of response to MTX in juvenile idiopathic arthritis. Follow-up in two smaller cohorts of 
429 and 177 RA patients did not support these findings, although these cohorts were more 
heterogeneous.   
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Introduction  
 
Rheumatoid arthritis (RA) is a common autoimmune inflammatory arthritis, with a 
significant effect on health and wellbeing. The first choice of treatment for RA patients for 
many years was monotherapy with the conventional synthetic disease-modifying anti-
rheumatic drug (csDMARD) methotrexate (MTX), with or without glucocorticoids1. However, 
a substantial proportion of patients do not respond adequately to treatment with MTX 
monotherapy2 at which point treatment may be escalated to combination csDMARDs or 
biological DMARDs (bDMARDs). Unfortunately, by this stage irreversible joint damage may 
have occurred3. This has led to the introduction of the treat-to-target approach, which 
advocates frequent clinical review and more rapid escalation to combination csDMARDs or 
bDMARDs in order to achieve remission or low disease activity, with good evidence that 
these are achieved more rapidly4, 5. Irrespective of the treatment protocol, MTX is the 
cornerstone of therapy in RA and is often continued in patients receiving bDMARDs6. 
 
It would be of both clinical and economic benefit to be able to target initial treatment, so 
that patients unlikely to respond to MTX monotherapy could be offered alternative 
therapies at an earlier stage. Genetic variants do not change over time and are easily 
measured; identifying genetic predictors of response to treatment could therefore be of 
great clinical utility if sufficiently predictive.   
 
A number of investigations of genetic predictors of response to MTX in RA patients have 
been published, but these have largely been candidate gene studies based on genes 
involved in MTX metabolism, including the folate pathway, and almost all have had small 
sample sizes7-10. A few genetic variants have been nominally associated with response in 
more than one study (rs2372536 in ATIC, reviewed in Plant et al.11) or in a meta-analysis 
(rs1051266 in SLC19A1 (RFC1)12), but results are inconsistent across studies and not close to 
reaching genome-wide significance levels. Senapati et al.13 carried out the first genome-
wide association (GWA) analysis of response to MTX monotherapy, in 457 RA patients from 
North India, comparing good and poor responders; they found 2 loci reaching significance 
levels of less than 10-5, but nothing reached genome-wide significance. Cobb et al.14 carried 
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out a GWA study of response to MTX in 759 European patients with juvenile idiopathic 
arthritis (JIA), identifying 14 regions reaching a significance level of less than 10-5.  
 
The clinical importance of this question motivated the formation of the international 
Pharmacogenomics of Methotrexate in RA (PAMERA) consortium and the UK MAximizing 
Therapeutic Utility in RA (MATURA) consortium (www.matura.whri.qmul.ac.uk), which has 
the wider remit of using blood-based biomarkers and pathobiology to inform the 
stratification of all stages of RA treatment15. In this study, we have combined data from 
these two consortia to report the first published GWA study of response to MTX 
monotherapy in RA patients of European ethnicity, based on a much larger sample size than 
previously reported studies.  
 
Subjects and Methods 
All component studies were approved by a Research Ethics Committee (see Supplementary 
Information) and all patients provided written informed consent for genetic studies. 
 
Study Population 
The study was split into two phases. The first phase comprised RA cases treated with MTX 
monotherapy, obtained from three observational UK studies [the Yorkshire Early Arthritis 
Register (YEAR)16, the Manchester Rheumatoid Arthritis Medication Study (RAMS)17 and the 
Leeds Inflammatory Arthritis disease CONtinuum registry (IACON)18], four UK-led clinical 
trials [Infliximab as inDuction therapy in Early rheumatoid Arthritis (IDEA)19, Etanercept and 
Methotrexate in Patients to Induce Remission in Early arthritis trial (EMPIRE)20, Combination 
Anti-Rheumatic Drugs in Early Rheumatoid Arthritis (CARDERA-1)21 and Effect of anakinra as 
combination therapy: second UK combination therapy in early rheumatoid arthritis trials 
(CARDERA-2)22], a US-led trial [Treatment of Early Aggressive Rheumatoid arthritis (TEAR)23], 
a Swedish trial [SWEdish FarmacOTherapy (SWEFOT)24] and a Dutch observational study 
[Synoviomics25]. Although 1952 patients on MTX monotherapy were genotyped, a maximum 
of 1424 were available for analysis after exclusions for high glucocorticoid use, missing 
clinical data or quality control (Supplementary Table 1). The second phase was used for 
follow-up and consisted of two datasets: Phase 2a cases were obtained from the Scottish 
Early Rheumatoid Arthritis (SERA) study26, and Phase 2b cases were from the MTX control 
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arms of three international clinical trials programs [a 3-trial program from the Actemra 
versus Methotrexate double-Blind Investigative Trial In mONotherapy (AMBITION) study27, a 
3-trial program involving MabThera/Rituximab28-30 and  a 4-trial program involving 
Ocrelizumab31]. 
 
For inclusion in Phase 1 of the study, individuals were required to have a consultant 
diagnosis of RA, a maximum of 12-month disease duration prior to starting MTX and to have 
started treatment with MTX monotherapy; those starting with any additional csDMARDs, 
bDMARDs or high dose oral glucocorticoid (relevant to the CARDERA studies) were excluded 
from analysis. The study was restricted to patients of self-reported European ancestry, 
further validated through SNP genotyping. Clinical measurements collected included 
swollen 28-joint count (SJC28), tender 28-joint count (TJC28) and C-reactive protein (CRP, in 
mg/L), or erythrocyte sedimentation rate (ESR), if CRP was not available. Measurements of 
these were taken at baseline (up to 6-weeks before the individual ?s MTX start date) and 
again at follow-up (6 months from the individual ?s MTX start date, or 3 months if either this 
was not available or the patient started any additional DMARD between 3 and 6 months). 
Three component disease activity scores DAS28CRP3 (calculated as 1.10[0.56(A?TJC28) + 
0.28(A?SJC28) + 0.36(loge(CRP+1))] + 1.15) and DAS28ESR3 (calculated as 1.08[0.56(A?TJC28) + 
0.28(A?SJC28) + 0.70(loge(ESR))] + 0.16) were calculated for each individual at baseline and 
follow-up.  
 
For Phase 2 of the study, there was some relaxation of the entry criteria. For Phase 2a, cases 
were not required to have started treatment on MTX monotherapy, and additional 
csDMARDs were permitted in combination with MTX. For Phase 2b, cases were all treated 
with MTX monotherapy, but were not required to have disease duration of less than 12 
months. 
 
Further information on the contributing studies is given in Supplementary Information. 
 
Genotyping 
Samples were genotyped using five different Illumina arrays (Supplementary Table 1), 
including (for one study) Immunochip, which has less than genome-wide coverage. Quality 
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control on samples and SNPs was performed separately for each of the genotype arrays. 
Samples were excluded for any of the following reasons: (i) a call-rate of <98% (of the total 
number of SNPs on the chip); (ii) evidence of non-European origin from principal 
components analysis using EIGENSTRAT32 after combining with HapMap and in-house 
European samples; (iii) sex as ascertained by genotyping not matching reported gender; (iv) 
evidence of first degree relationship or identity with another sample (in which case the 
sample with the lower call rate of the pair was excluded). SNPs were excluded for any of the 
following reasons: (i) Hardy ?Weinberg equilibrium p-value <10-6; (ii) call-rate <98%; (iii) 
minor allele frequency (MAF) <0.01. Imputation was conducted using IMPUTEv233 with the 
1,000 Genomes haplotypes Phase 3 integrated variant set as reference. Genotypes were 
phased within IMPUTEv2 and imputed in a 2Mb window (non-CoreExome genotyped 
samples) or pre-phased using SHAPEITv2-r83734 and imputed in a 7Mb window (CoreExome 
genotyped samples). The MCMC options used in IMPUTEv2 for all imputation were (k=80, 
iter=30, burnin=10) with effective size of population set as Ne=20000). Following 
imputation, only SNPs that had an INFO score >0.8 were retained for analysis.  
 
Ultra-low coverage whole-genome sequencing at a mean depth of 0.5x was available for the 
SERA participants. The raw sequencing reads were aligned to the HG19 reference genome 
using the Torrent 538 Mapping Alignment Program for Ion TorrentTM Data (TMAP) software. 
Imputation to the 1000 Genomes Phase 3 reference panel was performed using the 
GeneImp software35. Similarly to the genotype data, relatedness was evaluated based on a 
subset of the imputed genotypes thinned for linkage disequilibrium (LD) using PLINK36, and 
samples were excluded on evidence of a first-degree relationship with another sample. 
 
Statistical Analyses 
In Phase 1 of the study, four separate genome-wide analyses were conducted for change in 
outcome from baseline to follow-up (follow-up measure minus baseline measure) of DAS28 
(either DAS28CRP3 or DAS28ESR3 dependent on study), SJC28, TJC28 and loge(CRP+1); CRP 
measures were log-transformed because the distribution of measures was highly positively 
skewed. Imputed genotypes were analyzed as expected genotype counts based on the 
posterior probabilities (gene dosage) using linear regression implemented in SNPTEST237, 
assuming an additive genetic model, with baseline measure included as a covariate. As 
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outliers from count data may have a large influence on the fitted linear regression models 
for rarer SNPs, the results presented in this study are restricted to SNPs with a minor allele 
frequency >0.05. Analyses were performed separately for each of the three groups of 
studies measured on the same genotype array (see Figure 1), and meta-analysis was then 
conducted across groups using PLINK. A fixed effects model was used for the meta-analysis 
unless there was evidence of heterogeneity between the study arrays (I2>31%)38, in which 
case a random-effects model was used. To account for potential population stratification in 
the OmniExpressExome samples from the USA, UK, Sweden and the Netherlands, the first 
two principal components were included as covariates in the regression model. The analysis 
of the most significant SNPs was repeated including the first 5 principal components and 
had little effect on the results. All outcomes were mean-centered and scaled to have a 
variance of 1 within each group before the linear regression. Since ESR measures were used 
in place of CRP measures for the CARDERA and TEAR samples, the scaling for DAS28 was 
carried out separately for these studies.  
 
All regions that included a SNP with a p-value <10-5 and additional SNPs within 200Kb 
reaching p<5x10-5 were followed up in Phase 2. All SNPs within the region with a p-value 
<0.001 were tested using the same regression models as in Phase 1. Two separate genotype 
arrays were used for the Phase 2b samples (Figure 1), and data from the two arrays were 
meta-analysed using a fixed effects model. 
 
Follow-up of Candidate Genes and Previous Studies 
Candidate genes were identified based on their putative role in MTX metabolism and 
mechanism of action. MTX is a structural analogue of folic acid and interferes with the folate 
cycle through competitive inhibition of dihydrofolate reductase, which is important for the 
effective metabolism of biologically active folate cofactors. These are required for the 
generation of methionine from homocysteine and for the synthesis of purine and pyrimidine 
nucleosides. Within cells, MTX is rapidly converted to J-glutamyl polyglutamates that inhibit 
enzymes crucial for de novo synthesis of nucleotide precursor metabolites and ultimately 
inhibition of enzymes involved in adenosine metabolism. Relevant pathways, including drug 
transporters, were identified in the Pharmacogenomics Knowledgebase PharmGKB, using the 
ƐĞĂƌĐŚƚĞƌŵ “ŵĞƚŚŽƚƌĞǆĂƚĞ ? ?The rĞƐƵůƚĂŶƚƉĂƚŚǁĂǇƐǁĞƌĞ  “ŶƚŝŵĞƚĂďŽůŝƚĞWĂƚŚǁĂǇ ?ĂŶĚ
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 “DĞƚŚŽƚƌĞǆĂƚĞWĂƚŚǁĂǇ ?ĂŶĐĞƌĞůů ?WŚĂƌŵĂĐŽŬŝŶĞƚŝĐƐ ? ?Non-redundant genes listed under 
these headings were included as candidates. In addition, adenosine receptor genes listed in 
a recent MTX pathway PharmGKB39 summary were included in the analysis (Supplementary 
Table 2). All SNPs found within the genes were tested in Phase 1 for each of the 4 traits. 
 
Two previously reported genome-wide association studies of response to MTX were 
followed up using the results of our overall DAS28 analysis. The first was a study of 457 
Indian RA patients13 with an outcome classified as good response (a decrease in the 
DAS28ESR3 score by 1.2 and the final DAS28ESR3 A? ? ? ?ĨŽƌĂƚůĞĂƐƚ ?ŵŽŶƚŚƐĂĨƚĞƌMTX 
monotherapy) or poor response (duration of illness not exceeding 5 years and active disease 
(DAS28ESR3 A? ? ? ? ?ĚĞƐƉŝƚĞĂƚůĞĂƐƚ ?ŵŽŶƚŚƐŽĨ therapy with MTX). The second was a study 
of 374 European JIA patients14 categorized as responders according to the American College 
of Rheumatology paediatric 30, 50 and 70 improvement criteria or as non-responders. All 
SNPs with P<0.0001 in the discovery phase of these two studies were followed-up in our 
Phase 1 results for DAS28 outcome. Any such SNP which additionally reached p<0.01 in 
Phase 1 was followed up in Phase 2. 
 
Further details of methods used in the interpretation of results can be found in 
Supplementary Information.  
 
Results 
 
A total of 1424 RA cases passed quality control for Phase 1 (Supplementary Table 1), with 
the maximum number available for analysis dependent on the trait: 1392 for DAS28, 1424 
for SJC28/TJC28 and 1133 for CRP. The numbers were lower for areas of the genome not 
covered by Immunochip (1244 and 1276 for DAS28 and SJC28/TJC28 respectively, with 
number for CRP unchanged). Demographic and clinical characteristics are presented in Table 
1 and Supplementary Table 3. Starting doses of MTX ranged from 2.5 to 25mg, and highest 
mean baseline disease activity was observed in the patients from the CARDERA trials. 
 
No SNP reached genome-wide statistical significance (p<5x10-8) for any of the four 
outcomes. The most significant region, around the gene Neuregulin 3 (NRG3) on 
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chromosome 10, reached 9.8x10-8 for change in DAS28 (Table 2, Figure 2, Supplementary 
Figures 1-2). The SNP rs168201 in this region was also the SNP with the most consistent 
evidence of association over the four outcomes; rs168201 is an intronic variant in NRG3, 
having p=9.8x10-8 for DAS28 and p<0.01 for all 3 of the components SJC28, TJC28 and CRP 
(Figure 3).  
 
In total, 25 regions were identified harbouring SNPs with suggestive evidence for association 
with MTX response (p<10-5 for at least one SNP, and additional supporting SNPs within 
200kb reaching p<5x10-5). Only two regions reached this level of significance for change in 
CRP (around the genes KRASP1 and WNK2). The analysis of SJC28 identified the most 
regions reaching p<10-5, including regions encompassing the genes RWDD3, PARK2, 
COL25A1, THSD7B and THBD. The most significant region for TJC28 was at an intergenic 
region on chromosome 6 (Table 2). 
 
There were 429 RA cases available for analysis in Phase 2a, of whom only 154 (36%) were on 
MTX monotherapy, the remainder being on MTX in combination with one or more of 
prednisolone (116), sulfasalazine (155), hydroxychloroquine sulfate (175) and leflunomide 
(9). For Phase 2b, 177 cases were available, with 99 (53%) of these having disease duration 
greater than 12 months; mean baseline disease activity was higher than for Phase 1 cases 
(Table 1, Supplementary Table 3). All SNPs with p<0.001 in the 25 regions were followed up, 
but no SNP reached a level of p<0.001 in either Phase 2a or 2b (Table 2, Supplementary 
Tables 4-7).  
 
Details of the genes tested from the MTX metabolism candidate gene selection can be 
found in Supplementary Table 2. The number of SNPs tested for each gene ranged from 7 
(FPGS) to 643 (ADK) with 3168 tested in total (Supplementary Figure 3). The most significant 
SNP was rs7996393 for both DAS28 and TJC28, found in the gene AMPD1 (p=0.0008 and 
p=0.0011, respectively). For CRP, the most significant SNP was rs4148160 (p=0.0078) in 
ABCG2, and for SJC28 the most significant SNP was rs2236224 (p=0.0064) in MTHFD1. The 
genes selected included two SNPs nominally associated in more than one previous study. In 
ATIC, rs2372536 was not associated with DAS28, CRP or SJC28 (p=0.11, p=0.20 and p=0.83, 
respectively) but was nominally associated with TJC28 (beta (95% CI) = 0.06 (0.00, 0.13), 
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p=0.042). In SLC19A1, rs1051266 was not associated with DAS28, CRP, SJC28 or TJC28 
(p=0.76, p=0.46, p=0.24 and p=0.42, respectively). 
 
We used the results from the analysis of DAS28 to follow up all SNPs with p<10-4 in either of 
two previous GWA studies of response to MTX, of Indian RA patients and European JIA 
patients (Supplementary Table 8 and 9). No SNP from the Indian RA study showed evidence 
of association at p<0.01 in our results when taking direction of effect into account. One 
region of association at the ZMIZ1 gene in the JIA study showed some evidence of 
association in our results (rs703979: p=7.7x10-4 in the JIA study, p=1.1x10-4 for DAS28 in this 
study, and rs703970: p=8.3x10-5 in the JIA study, p=1.8x10-4 for DAS28 in this study) with 
corresponding directions of effect. When uƐŝŶŐ&ŝƐŚĞƌ ?ƐŵĞƚŚŽĚĨŽƌcombining p-values 
across the JIA study and this study, this gives 1.4x10-6 for rs703979 and 2.8x10-7 for 
rs703970. These two SNPs are in almost complete LD (r2=0.98 for the OmniExpressExome 
samples). 
 
Discussion 
 
This study is by far the largest GWA study of response to MTX in RA patients reported to 
date. Although no SNP showed association with response at a genome-wide level, several of 
the findings are of potential interest. 
 
The SNP showing the most significant association with DAS28 (or any outcome) is rs168201, 
an intronic variant in NRG3. In an early GWA study40, rs10509440 in NRG3 was reported to 
show some evidence of association with RA susceptibility (p=6 x 10-5), with weak supportive 
evidence from a neighbouring SNP, rs12358407, in a follow-up study (p=0.003)41.  These 
findings have however not been replicated in more recent larger GWA studies. SNPs in the 
SFTPD gene close to NRG3 have been associated with RA susceptibility at a genome-wide 
significance level in Asian but not European populations (rs726288)42; these SNPs are not in 
LD with the previously reported NRG3 SNPs. 
 
NRG3 encodes a cell-cell signaling protein (NRG3), which is a ligand for the ERBB4 (HER4) 
receptor tyrosine kinase43. There is some evidence linking NRG3 signaling to MTX response. 
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Knock-down of the NRG3 receptor, ERBB4 (HER4), in osteosarcoma cell lines increased 
sensitivity to MTX (60% increase in apoptosis) but not other chemotherapies44. In a 
peripheral blood monocyte study of 32 RA patients treated with anakinra and MTX, NRG3 is 
one of 7 genes in a gene signature predicting response, being up-regulated in therapeutic 
non-responders45. High resolution (5kb) Hi-C data in the GM12878 B lymphoblastoid cell line 
(see Supplementary Information) shows that rs168201 interacts most significantly with the 
NRG3 promoter, underlining it as a candidate. From promoter capture Hi-C data in a 
GM12878 B cell line46, it is seen that a DNA fragment ~100kb from the LD block around 
rs168201 shows some evidence of interaction (CHiCAGO score = 5.41)47 with the promoter 
of MAT1A (around 2.5Mb upstream of rs168201), encoding methionine S-
adenosyltransferase (MAT), a key enzyme in the transmethylation cycle. However, we were 
unable to demonstrate that the associated variants were in linkage disequilibrium with 
known eQTL in NRG3 or MAT1A, nor splice QTL in NRG3. This gene is of interest because 
low-dose MTX has been shown to inhibit its expression and activity48. 
 
Previously reported findings and candidate genes from the MTX metabolism pathway were 
followed up in this study, but little evidence was seen for their association with response. A 
number of these genes showed weak chromatin interactions in GM12878 cells with SNPs 
from the top 25 regions (e.g. ADK with rs703987, a SNP associated with change in DAS28). 
These interactions are listed in Supplementary Table 10.  
 
The strongest support from candidate gene analyses was for SNPs in ZMIZ1, one of three 
genes highlighted in a GWA study of response to MTX in JIA patients14. This gene is involved 
in transcription factor regulation and has been associated with several autoimmune 
diseases, including psoriasis, CƌŽŚŶ ?ƐĚŝƐĞĂƐĞ49 and multiple sclerosis (MS)50. Fewings et al. 
have recently shown that expression of ZMIZ1 varies in response to vitamin D and to certain 
MS therapies and may indicate a type of immune dysregulation potentially related to 
therapeutic response51.  
 
The top 25 loci were also annotated using two approaches - high-resolution long-range 
chromatin interaction and correlating regional genetic scores with genetic scores for other 
traits (see Supplementary Information and Supplementary Table 11). A few of the 
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candidates from the Hi-C analysis have been indicated in inflammation biology, e.g. NINJ1 
and RWDD352, 53. The intergenic region on chromosome 6 most strongly associated with 
change in TJC28 interacts with the CCDC167 promoter in GM12878 B lymphoblastoid cells, a 
gene which is highly expressed in the immune system. In addition, rs9910936, also 
associated with change in TJC28, is close to several genes, but this analysis shows that the 
most relevant gene is likely to be EFTUD2, since the SNP is an expression-quantitative-trait 
locus for this gene and also shows chromatin interaction. Interestingly, some of the SNPs in 
the NRG3 region of association interact with the ZMIZ1 promoter, but the interaction is 
much weaker than with the NRG3 promoter, so this is not shown as a candidate in 
Supplementary Table 11. 
 
Progress is slow in identifying genetic predictors of treatment response, and a recent 
collaborative effort to identify genetic predictors of response to anti-TNF was not able to 
significantly improve predictive performance relative to standard clinical traits54. Although 
this is by far the largest study of MTX response to date, it is still small compared with 
current genome-wide studies of disease susceptibility. The study had 86% power to detect a 
genetic variant explaining 3% of the variance in outcome at a genome-wide significance 
level, but a sample size of at least 4000 patients would be needed to have over 80% power 
to detect a variant explaining only 1% of the variance. The challenge for pharmacogenetics 
is to assemble large cohorts of sufficiently homogeneous patients. Efforts were made in this 
study to minimize heterogeneity by using strict entry criteria. Inevitably, there was 
heterogeneity in the rate of escalation of MTX dose, however, most studies aimed for a 
dose between 15-20mg within the first six weeks. Outcome measures are difficult to 
measure consistently, and there was a need to scale DAS28-CRP and DAS28-ESR separately, 
since only the latter measure was collected for the CARDERA and TEAR cohorts.  Although 
overall measures such as DAS28 are important clinically, the analysis was also carried out on 
its individual components, since some of these are more heritable55 and more objective 
than others. For clinical interest, ĂŶĂůǇƐĞƐŽĨ “ƌĞsƉŽŶĚĞƌƐ ? ?Ăny response versus no 
response, and good response versus no response, according to EULAR criteria56) were also 
carried out (Supplementary Tables 12 and 13). Results were similar to those from the 
analysis of DAS28 but generally less highly significant.   
 
 14 
This analysis suggests that no individual common variants are likely to be sufficiently 
predictive of response to be of clinical utility, but with larger studies it may be possible to 
create genetic risk scores, which, in combination with other factors, can be of use to target 
initial treatment. Larger sample sizes are needed, together with follow-up of the potentially 
interesting findings reported here.   
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Figure legends 
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Figure 1. Study design. Study names are given in italics. (*) indicates ESR was used in the 
DAS28 calculation for that study instead of CRP. 
 
Figure 2. Results for the SNP (rs168201) reaching the highest level of significance from the 
linear regression of change in DAS28 in phase 1 of the study. (a) -log10 P-values from Phase 1 
for the SNPs surrounding rs168201 on chromosome 10. (b) Forest plot of estimated per 
allele betas for the effect of rs168201 on change in DAS28 in number of standard deviations 
by study phase. 
 
Figure 3. Results in all traits for the lead SNP of the 25 most highly associated regions 
identified in Phase 1 in DAS28, CRP, SJC28 or TJC. 
 
Table 1. Summary of the demographics and clinical characteristics for the patients included in the analysis for Phase 1 and 2. 
 
Study 
Sample 
Origin N Age (years) Female 
RF 
positive 
Mean 
Duration < 1 
year 
MTX Starting 
Dose (mg) 
Baseline 
DAS28 
      Mean (SD) N (%) N (%)  Min Max Mean (SD) 
Phase 1              
YEAR UK 343 58.3 (13.1) 239 (70) 243 (73) Yes 5 22.5 5.0 (1.2) 
TEARa US 117 49.8 (12.0) 91 (66) 118 (86) Yes 2.5 10 5.6 (1.0) 
SWEFOT Sweden 325 53.9 (14.0) 233 (71) 225 (69) Yes 10 10 5.1 (0.9) 
Netherlands Netherlands 38 54.7 (12.2) 26 (68) 22 (58) Yes 7.5 20 4.6 (1.2) 
RAMS UK 274 56.8 (14.1) 190 (69)   Yes 2.5 25 4.4 (1.2) 
IDEA UK 29 54.6 (12.0) 24 (69) 24 (71) Yes 10 15 4.9 (1.3) 
IACON UK 128 59.5 (13.5) 91 (66) 78 (59) Yes 5 25 4.3 (1.3) 
EMPIRE UK 22 53.1 (12.8) 17 (74) 14 (61) Yes 10 10 4.2 (0.9) 
CARDERA Trialsa UK 148 54.4 (12.9) 108 (67) 101 (68) Yes 7.5 7.5 5.8 (1.1) 
Phase 2a              
SERA UK 429 58.4 (13.2) 279 (65) 169b (65) Noc 5 30 4.8 (1.2) 
Phase 2b              
AMBITION International 85 52.5 (13.8) 69 (74) 62 (67) No 7.5 7.5 6.0 (0.8) 
MabThera Trials International 32 49.6 (12.5) 23 (72) 29 (91) No 7.5 7.5 5.7 (0.9) 
Ocrelizumab Trials International 60 51.7 (11.1) 42 (70) 55 (92) No 7.5 7.5 6.0 (0.9) 
Abbreviations: DAS28, disease activity score in 28 joints (3 component CRP version); RF, Rheumatoid Factor; SD, standard deviation. a CRP 
not available, DAS28 calculated using ESR. b Data available for 262 samples. c Median symptom duration 172 days. 
 
Table 2. Summary of the most highly associated regions at P < 1  10-5 identified in Phase 1 for each of the 4 traits analysed genome-wide. 
 
          Phase 1 Phase 2a Phase 2b   
Trait Marker Chr Position 
Effect 
Allele 
Allele 
Frequ
ency 𝛃a (95% CI) P-value I2 (%)  𝛃a (95% CI) 
P-
value 𝛃a (95% CI) 
P-
value Genesb 
DAS28 rs2372751 3 81124821 C 0.49 0.17 (0.10, 0.24) 2.8 10-6 0 -0.02 (-0.14, 0.10) 0.77 0.13 (-0.08, 0.34) 0.23 LINC02027 
 
rs58840038 5 125773164 T 0.31 -0.17 (-0.24, -0.09) 8.0 10-6 0 -0.04 (-0.16, 0.09) 0.57 0.03 (-0.16, 0.23) 0.73 GRAMD3 
 
rs6903359 6 21986214 C 0.13 -0.23 (-0.34, -0.13) 7.4 10-6 0 0.07 (-0.12, 0.27) 0.46 0.10 (-0.17, 0.38) 0.45 CASC15 
 
rs168201 10 84610081 G 0.48 0.18 (0.12, 0.25) 9.8 10-8 0 -0.10 (-0.21, 0.02) 0.091 0.08 (-0.10, 0.26) 0.38 NRG3 
 
rs57816977 18 4012466 C 0.18 -0.22 (-0.31, -0.12) 5.3 10-6 0 0.12 (-0.03, 0.27) 0.10 0.00 (-0.24, 0.25) 1.00 DLGAP1 
               
loge(CRP+1) rs79244342 6 54660244 G 0.09 -0.26 (-0.37, -0.15) 3.3 10-6 0 -0.05 (-0.24, 0.13) 0.57 0.02 (-0.34, 0.37) 0.93 KRASP1 
 
rs1889339 9 96053928 G 0.18 0.19 (0.11, 0.27) 5.7 10-6 0 -0.06 (-0.20, 0.07) 0.38 0.17 (-0.05, 0.39) 0.14 WNK2 
              
SJC28 rs35179427 1 95670888 A 0.08 0.21 (0.12, 0.30) 7.8 10-6 0 -0.05 (-0.20, 0.09) 0.49 -0.25 (-0.54, 0.04) 0.10 
RWDD3 
TMEM56-
RWDD3 
 
rs1453301 2 138080695 A 0.16 0.15 (0.09, 0.22) 7.1 10-6 0 -0.05 (-0.16, 0.06) 0.39 -0.03 (-0.22, 0.17) 0.79 THSD7B 
 
rs77458347 4 109896081 T 0.14 0.18 (0.10, 0.26) 6.7 10-6 0 -0.02 (-0.14, 0.10) 0.77 0.18 (-0.10, 0.47) 0.21 COL25A1 
 
rs144940912 4 155092290 T 0.07 0.26 (0.15, 0.36) 1.4 10-6 16 0.11 (-0.05, 0.27) 0.20 0.11 (-0.32, 0.53) 0.62 
 
 
rs12663189 6 162730663 C 0.43 0.12 (0.07, 0.17) 2.0 10-6 0 -0.01 (-0.09, 0.08) 0.87 0.04 (-0.12, 0.20) 0.64 PARK2 
 
rs314637 7 4421893 A 0.22 0.15 (0.08, 0.21) 2.9 10-6 13 0.08 (-0.02, 0.18) 0.11 0.19 (-0.01, 0.38) 0.06 
 
 
rs113798271 7 145059089 G 0.21 0.14 (0.08, 0.21) 9.4 10-6 29 0.02 (-0.08, 0.12) 0.67 0.02 (-0.16, 0.21) 0.81 
 
 
rs1175813 19 49737486 G 0.11 0.20 (0.12, 0.29) 1.4 10-6 0 -0.15 (-0.27, -0.03) 0.012 0.00 (-0.24, 0.25) 0.98 
 
 
rs1042579 20 23028724 A 0.23 0.15 (0.08, 0.21) 6.9 10-6 0 0.02 (-0.09, 0.12) 0.76 0.24 (0.04, 0.44) 0.020 THBD 
 
rs2836915 21 40509189 T 0.31 -0.13 (-0.18, -0.07) 4.5 10-6 0 -0.05 (-0.14, 0.04) 0.26 -0.06 (-0.24, 0.12) 0.51 
 
              
TJC28 rs10058818 5 56808696 G 0.21 0.17 (0.10, 0.25) 2.4 10-6 8 0.06 (-0.06, 0.17) 0.31 -0.10 (-0.32, 0.12) 0.37 LINCR-0003 
 
rs10515242 5 95982675 C 0.06 0.28 (0.16, 0.40) 4.8 10-6 0 0.17 (-0.01, 0.35) 0.069 -0.08 (-0.42, 0.26) 0.64 
 
 
rs2026708 6 21986895 G 0.14 -0.22 (-0.31, -0.13) 1.9 10-6 0 0.02 (-0.14, 0.19) 0.78 0.06 (-0.19, 0.30) 0.65 CASC15 
 
rs2776898 6 37541111 T 0.35 0.16 (0.10, 0.23) 9.9 10-7 0 -0.11 (-0.21, -0.01) 0.027 0.14 (-0.03, 0.32) 0.11 
 
 
rs114461403 7 16547268 T 0.33 0.15 (0.08, 0.21) 7.5 10-6 0 0.00 (-0.11, 0.10) 0.98 -0.12 (-0.30, 0.07) 0.21 
 
 
rs28442057 15 55110958 T 0.34 0.14 (0.08, 0.21) 7.9 10-6 0 -0.01 (-0.11, 0.09) 0.82 0.04 (-0.15, 0.22) 0.68 
 
 
rs12446816 16 14092341 G 0.38 0.15 (0.09, 0.21) 5.1 10-6 0 -0.01 (-0.11, 0.08) 0.77 0.01 (-0.16, 0.17) 0.95 
 
  rs9910936 17 42949168 T 0.28 0.15 (0.09, 0.22) 6.7 10-6 0 0.05 (-0.06, 0.16) 0.38 0.08 (-0.11, 0.28) 0.40 
CCDC103 
EFTUD2 
GFAP KIF18B 
Abbreviations: DAS28, disease activity score in 28 joints; CRP, C-reactive protein; SJC28, swollen joint count 28; TJC tender joint count 28; Chr chromosome; 𝛃 beta; CI confidence interval; I2 
Heterogeneity statistic a Per-allele for change in outcome in number of standard deviations, positive values correspond to worse response. b SNP or supporting SNPs with P<5x10-5 located 
within gene. 
 
 
∆	Response	Trait
DAS28,	loge(CRP+1)	,	SJC28,	TJC28
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